<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02731911</url>
  </required_header>
  <id_info>
    <org_study_id>CMO-AP-EYE-0438</org_study_id>
    <nct_id>NCT02731911</nct_id>
  </id_info>
  <brief_title>Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study</brief_title>
  <official_title>Phase 4, Open-label, Non-randomized, Prospective Study of OZURDEX® in the Treatment of Diabetic Macular Oedema - The AUSSIEDEX Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study will assess Ozurdex in the treatment of Diabetic Macular Oedema in
      clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 29, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in Best Corrected Visual Acuity (BCVA) from baseline</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in Central Retinal Thickness (CRT) from baseline</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a BCVA improvement of 15 letters or more</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a BCVA improvement of 10 letters or more</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCVA average mean from baseline in area under the curve (AUC) analysis</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Intraocular Pressure (IOP)-lowering treatments used to control IOP increase</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BCVA at each injection number</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in BCVA at each injection number</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in BCVA across all the study injection numbers</measure>
    <time_frame>Baseline, 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with BCVA improvement</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of BCVA losers</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients improving to 20/40 or better</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of Ozurdex injections</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean interval between Ozurdex® injections</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in central subfield retinal thickness by Optical Coherence Tomography (OCT) before each follow-up injection number</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">202</enrollment>
  <condition>Diabetic Macular Oedema</condition>
  <arm_group>
    <arm_group_label>Ozurdex® (dexamethasone intravitreal implant)</arm_group_label>
    <description>Patients who received Ozurdex® in the treatment of Diabetic Macular Oedema per local standard of care in clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone intravitreal implant</intervention_name>
    <description>Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice.</description>
    <arm_group_label>Ozurdex® (dexamethasone intravitreal implant)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are pseudophakic, or phakic and scheduled for a cataract operation, and with a
        diagnosis of Diabetic Macular Oedema in one or both eyes who are to be treated with
        Ozurdex® at least once as determined by their physician.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pseudophakic or phakic and scheduled for a cataract operation

          -  Macular oedema due to DME

        Exclusion Criteria:

          -  Previous Ozurdex® treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. George Labib</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina and Macula Specialists,Hurstville</name>
      <address>
        <city>Hurtsville</city>
        <state>New South Wales</state>
        <zip>2220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina and Macula Specialists, Miranda</name>
      <address>
        <city>Miranda</city>
        <state>New South Wales</state>
        <zip>2228</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Doctors Mona Vale</name>
      <address>
        <city>Mona Vale</city>
        <state>New South Wales</state>
        <zip>2103</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marsden Eye Clinic</name>
      <address>
        <city>Parramatta</city>
        <state>New South Wales</state>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina &amp; Vitreous Centre Strathfield</name>
      <address>
        <city>Strathfield</city>
        <state>New South Wales</state>
        <zip>2135</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strathfield Retina</name>
      <address>
        <city>Strathfield</city>
        <state>New South Wales</state>
        <zip>2135</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina &amp; Vitreous Centre City</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Eye and Retina Clinic</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Eye Hospital/Macular Diseases Centre</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney West Retina</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terrace Eye Centre</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caboolture Eye Surgery</name>
      <address>
        <city>Caboolture</city>
        <state>Queensland</state>
        <zip>4510</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Eye Hospital</name>
      <address>
        <city>Redcliffe</city>
        <state>Queensland</state>
        <zip>4020</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Qld Eye Institute</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adelaide Eye &amp; Retina Centre</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Opthalmology, Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hobart Eye Surgeons</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tasmanian Eye Institute</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7249</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essendon Retina</name>
      <address>
        <city>Essendon</city>
        <state>Victoria</state>
        <zip>3040</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Parade Eye Consultants</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vision Eye Institute</name>
      <address>
        <city>Footscry</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lions Eye Institute</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2016</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

